CD1530
Based on 3 publication(s) in Google Scholar
CD1530 is an orally active, selective RARγ agonist and antibacterial agent. CD1530 reduces Smad1/5/8 phosphorylation and overall Smad levels. CD1530 reduces β-catenin, MMP9 protein, and ROS levels. CD1530 exhibits activities such as inhibiting heterotopic ossification, promoting Achilles tendon healing, and inhibiting muscle fatty infiltration. CD1530 can be used in the research of orthopedic diseases (such as heterotopic ossification, Achilles tendon injury), muscle diseases (such as muscle fatty infiltration-related diseases).
For research use only. We do not sell to patients.
- Purity: 98.01%
- CAS No.: 107430-66-0
- Formula: C27H26O3
- Molecular Weight:398.49
-
Storage:Powder -20°C, 3 years , 4°C, 2 years ; In solvent -80°C, 6 months , -20°C, 1 month
To place orders, for customer services and technical support, please contact: MedChemExpress USA
Tel: 609-228-6898 E-mail: [email protected] [email protected]
-
Biological Activity
-
Chemical Information
-
Solvent & Solubility
- Purity & Documentation
- References
-
Help & FAQs
-
Anti-Infection Compound Library
HY-L002
-
Immunology/Inflammation Compound Library
HY-L007
-
Metabolism/Protease Compound Library
HY-L012
-
NF-κB Signaling Compound Library
HY-L014
-
Stem Cell Signaling Compound Library
HY-L017
-
TGF-beta/Smad Compound Library
HY-L018
-
Wnt/Hedgehog/Notch Compound Library
HY-L020
-
Anti-Cancer Compound Library
HY-L025
-
Anti-Aging Compound Library
HY-L034
-
Differentiation Inducing Compound Library
HY-L038
-
Reprogramming Compound Library
HY-L039
-
Antibacterial Compound Library
HY-L049
-
Cytoskeleton Compound Library
HY-L060
-
Orally Active Compound Library
HY-L061
-
Neuroprotective Compound Library
HY-L070
-
Anti-Breast Cancer Compound Library
HY-L074
-
Anti-Pancreatic Cancer Compound Library
HY-L077
-
Angiogenesis-Related Compound Library
HY-L088
-
Transcription Factor-Targeted Library
HY-L090
-
Anti-Liver Cancer Compound Library
HY-L101
-
Anti-Colorectal Cancer Compound Library
HY-L103
-
Anti-Prostate Cancer Compound Library
HY-L124
-
Anti-Pulmonary Fibrosis Compound Library
HY-L125
-
Nuclear Receptor Compound Library
HY-L126
-
Osteogenesis Compound Library
HY-L131
-
Cancer Stem Cells Compound Library
HY-L135
-
Pain-Related Compound Library
HY-L139
-
Antihypertensive Compound Library
HY-L145
-
Metabolic Enzyme Compound Library
HY-L146
-
Protease Inhibitor Library
HY-L147
-
Highly Selective Inhibitors Library
HY-L158
-
Highly Selective Activators Library
HY-L159
-
Extracellular Vesicles (EVs) Compound Library
HY-L168
-
Anti-Ovarian Cancer Compound Library
HY-L173
-
Multi-Target Compound Library
HY-L176
-
Bioactive Compound Library Max
HY-L181
-
MCE Bioactive Compound Library
HY-L001V
-
Bioactive Compound Library
HY-L001
-
Anti-Gastric Cancer Compound Library
HY-L184
-
Anti-Fibrosis Compound Library
HY-L185
-
Cell Proliferation Compound Library
HY-L201
-
High-Throughput Bioactive Compound Library
HY-L205
-
Lactylation Compound Library
HY-L249
Publications Citing Use of MedChemExpress (MCE) CD1530
More
Biological Activity
CD1530 (1 μM; 24 h) enhances the expression of UCP1 in mature mouse adipocytes[2].
CD1530 (10-1000 nM; 48 h-3 weeks) significantly enhances the migratory capacity of injured Achilles tendon-derived tendon fibroblasts (iATF) and inhibits the chondrogenic differentiation of iATF[4].
CD1530 (10 μg/mL; 2 h) reduces the number of methicillin-resistant Staphylococcus aureus (MRSA) below the limit of detection, demonstrating potent in vitro bactericidal activity[5].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
-
Cell Line:Injured Achilles tendon-derived tendon fibroblasts (iATF)
-
Concentration:100 nM, 1000 nM
-
Incubation Time:3 weeks
-
Result:Inhibited the chondrogenic differentiation of iATF at 100 nM and 1000 nM.
Showed smaller iATF pellets no Safranin-O positive area.
Reduced the expression of chondrogenic marker genes Col2a1 and Col10a1.
CD1530 (2.5 mg/100 mL; p.o., in drinking water; frequency not mentioned; 15 weeks) combined with 4-nitroquinoline 1-oxide reduces the number and severity of tongue tumor lesions in mice with oral cancer[3].
CD1530 (10 μg; local injection; 3 times per week; 3 weeks) accelerates tendon healing in mice with Achilles tendon rupture, inhibits cartilage formation, reduces fibrous tissue-like scar formation, and promotes better collagen fiber alignment[4].
CD1530 (4 mg/kg, p.o.; or 1 mM, intramuscular injection; once a day; administration for 4 weeks) can inhibit muscle fat infiltration, reduce the number of intramuscular adipocytes, and reduce the expression of adipogenic marker genes in mice with rotator cuff tear[6].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
-
Animal Model:C57BL/6 male mice (weight approximately 23 g, 9 weeks old) + rotator cuff tear model[6]
-
Dosage:4 mg/kg (orally administered); 1 mM (intramuscular injection, solvent: dimethyl sulfoxide)
-
Administration:Oral administration, once a day, for 4 weeks; Intramuscular injection, once a week, for 4 weeks
-
Result:Significantly suppressed fatty infiltration in the supraspinatus muscle (p.o.).
Reduced the ratio of the fat area to the muscle cross-sectional area and the expression of adipogenic marker genes Pparg and Cebpa (p.o.).
Reduced fatty infiltration in the supraspinatus muscle (intramuscular injection).
Chemical Information
-
CAS No. 107430-66-0
-
Appearance Solid
-
Molecular Weight 398.49
-
Formula C27H26O3
-
Color Light yellow to brown
-
SMILES
O=C(O)C1=CC=C(C2=CC=C3C=C(O)C(C4(C5)CC6CC5CC(C6)C4)=CC3=C2)C=C1
-
Shipping
Room temperature in continental US; may vary elsewhere.
-
Storage
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month
Publications (3)
-
Journal Impact Factor
-
Most Recent
-
Cell Stem Cell
CRISPRi/a screens in human iPSC-cardiomyocytes identify glycolytic activation as a druggable target for doxorubicin-induced cardiotoxicity. [Abstract]2024 Dec 5;31(12):1760-1776.e9. PMID: 39515331 -
Nat Cell Biol
A continuous totipotent-like cell-based embryo model recapitulates mouse embryogenesis from zygotic genome activation to gastrulation. [Abstract]2025 Oct 15. PMID: 41094030 -
Exp Cell Res
Yak FGF12 promotes the proliferation of fibroblasts and longissimus lumborum development. [Abstract]2025 Aug 1;451(1):114696. PMID: 40780388
Solvent & Solubility
DMSO : 100 mg/mL (250.95 mM; Need ultrasonic; Hygroscopic DMSO has a significant impact on the solubility of product, please use newly opened DMSO)
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month. When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month. When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
Select the appropriate dissolution method based on your experimental animal and administration route.
- For the following dissolution methods, please ensure to first prepare a clear stock solution using an In Vitro approach and then sequentially add co-solvents:
- To ensure reliable experimental results, the clarified stock solution can be appropriately stored based on storage conditions. As for the working solution for In Vivo experiments, it is recommended to prepare freshly and use it on the same day.
- The percentages shown for the solvents indicate their volumetric ratio in the final prepared solution. If precipitation or phase separation occurs during preparation, heat and/or sonication can be used to aid dissolution.
Add each solvent one by one: 10% DMSO 40% PEG300 5% Tween-80 45% Saline
Solubility: ≥ 2.5 mg/mL (6.27 mM); Clear solution
This protocol yields a clear solution of ≥ 2.5 mg/mL (saturation unknown).
Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (25.0 mg/mL) to 400 μL PEG300, and mix evenly; then add 50 μL Tween-80 and mix evenly; then add 450 μL Saline to adjust the volume to 1 mL.
Preparation of Saline: Dissolve 0.9 g sodium chloride in ddH₂O and dilute to 100 mL to obtain a clear Saline solution.
Add each solvent one by one: 10% DMSO 90% (20% SBE-β-CD in Saline)
Solubility: ≥ 2.5 mg/mL (6.27 mM); Clear solution
This protocol yields a clear solution of ≥ 2.5 mg/mL (saturation unknown).
Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (25.0 mg/mL) to 900 μL 20% SBE-β-CD in Saline, and mix evenly.
Preparation of 20% SBE-β-CD in Saline (4°C, storage for one week): 2 g SBE-β-CD powder is dissolved in 10 mL Saline, completely dissolve until clear.
Please enter the basic information of animal experiments:
-
-
-
-
Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.
Please enter your animal formula composition:
-
%DMSO +
Recommended: Keep the proportion of DMSO in working solution below 2% if your animal is weak.
-
%+
-
+%Tween-80 + +
-
%Saline +
The co-solvents required include: DMSO, . All of co-solvents are available by MedChemExpress (MCE). , Tween 80. All of co-solvents are available by MedChemExpress (MCE).
Working solution concentration: 0.22 mg/mL
Method for preparing stock solution: mg drug dissolved in μL DMSO. Stock solution concentration: mg/mL.
1. Take μL DMSO stock solution;
2. Add μL .
μL , mix evenly;
3. Then add μL Tween 80, mix evenly;
4. Then add μL
Please ensure that the stock solution in the first step is dissolved to a clear state, and add co-solvents in sequence. You can use ultrasonic heating (ultrasonic cleaner, recommended frequency 20-40 kHz), vortexing, etc. to assist dissolution.
Purity & Documentation
-
Data Sheet (280 KB)
-
SDS (393 KB)
- English - EN (393 KB)
- Français - FR (393 KB)
- Deutsch - DE (393 KB)
- Norwegian - NO (393 KB)
- Español - ES (393 KB)
- Swedish - SV (393 KB)
- Italian - IT (393 KB)
- Korean - KR (393 KB)
- Portuguese - PT (393 KB)
-
Handling Instructions (2659 KB)
References
[1]. Shimono K, et al. Potent inhibition of heterotopic ossification by nuclear retinoic acid receptor-γ agonists. Nat Med. 2011 Apr;17(4):454-60. [Content Brief]
[2]. Murholm M, et al. Retinoic acid has different effects on UCP1 expression in mouse and human adipocytes. BMC Cell Biol. 2013 Sep 23;14:41. [Content Brief]
[3]. Tang XH, et al. Combination of bexarotene and the retinoid CD1530 reduces murine oral-cavity carcinogenesis induced by the carcinogen 4-nitroquinoline 1-oxide. Proc Natl Acad Sci U S A. 2014 Jun 17;111(24):8907-12. [Content Brief]
[4]. Yimiti D, et al. CD1530, selective RARγ agonist, facilitates Achilles tendon healing by modulating the healing environment including less chondrification in a mouse model. J Orthop Res. 2025 Feb;43(2):273-284. [Content Brief]
[5]. Kim W, et al. A new class of synthetic retinoid antibiotics effective against bacterial persisters. Nature. 2018 Apr 5;556(7699):103-107. [Content Brief]
[6]. Shirasawa H, et al. Retinoic Acid Receptor Agonists Suppress Muscle Fatty Infiltration in Mice. Am J Sports Med. 2021 Feb;49(2):332-339. [Content Brief]
Complete Stock Solution Preparation Table
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month. When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.
| Optional Solvent | Concentration Solvent Mass | 1 mg | 5 mg | 10 mg | 25 mg |
|---|---|---|---|---|---|
| DMSO | 1 mM | 2.5095 mL | 12.5474 mL | 25.0947 mL | 62.7368 mL |
| 5 mM | 0.5019 mL | 2.5095 mL | 5.0189 mL | 12.5474 mL | |
| 10 mM | 0.2509 mL | 1.2547 mL | 2.5095 mL | 6.2737 mL | |
| 15 mM | 0.1673 mL | 0.8365 mL | 1.6730 mL | 4.1825 mL | |
| 20 mM | 0.1255 mL | 0.6274 mL | 1.2547 mL | 3.1368 mL | |
| 25 mM | 0.1004 mL | 0.5019 mL | 1.0038 mL | 2.5095 mL | |
| 30 mM | 0.0836 mL | 0.4182 mL | 0.8365 mL | 2.0912 mL | |
| 40 mM | 0.0627 mL | 0.3137 mL | 0.6274 mL | 1.5684 mL | |
| 50 mM | 0.0502 mL | 0.2509 mL | 0.5019 mL | 1.2547 mL | |
| 60 mM | 0.0418 mL | 0.2091 mL | 0.4182 mL | 1.0456 mL | |
| 80 mM | 0.0314 mL | 0.1568 mL | 0.3137 mL | 0.7842 mL | |
| 100 mM | 0.0251 mL | 0.1255 mL | 0.2509 mL | 0.6274 mL |
CD1530 Related Classifications
HY-108527 Related Classifications
Powered by Bioz